Open access chemical and clinical probes to support drug discovery
about
Open access chemical probes for epigenetic targetsSTITCH 2: an interaction network database for small molecules and proteinsThe Role of Medical Structural Genomics in Discovering New Drugs for Infectious DiseasesSelective Inhibitors of the JMJD2 Histone Demethylases: Combined Nondenaturing Mass Spectrometric Screening and Crystallographic ApproachesComprehensive characterization of the Published Kinase Inhibitor SetDiscovery and optimization of small-molecule ligands for the CBP/p300 bromodomainsOpen access target validation is a more efficient way to accelerate drug discoveryCyberinfrastructure for Open Science at the Montreal Neurological InstituteUse and misuse of material transfer agreements: lessons in proportionality from research, repositories, and litigationOpen source drug discovery - a limited tutorialUnmet challenges of structural genomicsOpen Access Could Transform Drug Discovery: A Case Study of JQ1.SGC--structural biology and human health: a new approach to publishing structural biology resultsAre patents impeding medical care and innovation?Development of homogeneous luminescence assays for histone demethylase catalysis and binding.Health diplomacy: a new approach to the Muslim world?Recent trends and observations in the design of high-quality screening collections.Probing the probes: fitness factors for small molecule tools.High-throughput production of human proteins for crystallization: the SGC experience.New approaches to rewarding pharmaceutical innovation.Identifying mechanism-of-action targets for drugs and probes.[1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomainsThe why and how of phenotypic small-molecule screens.Biophysical screening for the discovery of small-molecule ligands.Drug discovery for neglected tropical diseases at the Sandler Center.US academic drug discovery.Ligand and Target Discovery by Fragment-Based Screening in Human Cells.Establishing a reliable framework for harnessing the creative power of the scientific crowdPersonalized genomic disease risk of volunteers.The innovative medicines initiative: a public private partnership model to foster drug discovery.Recalibrating intellectual property rights to enhance translational research collaborations.An end to the myth: there is no drug development pipeline.Clinical cancer research: the past, present and the future.A call for sharing: adapting pharmaceutical research to new realities.Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction.Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.Public-Private Partnerships in Lead Discovery: Overview and Case Studies.Towards a more robust approach to selecting and prosecuting promising targets and compounds.More Haste, Less Speed: Could Public-Private Partnerships Advance Cellular Immunotherapies?An Aggregation Advisor for Ligand Discovery.
P2860
Q26781872-758F60A4-B579-4FD4-8762-177179E94A11Q27137016-3651D979-E5A7-4058-BF1F-DD12CD6908C4Q27489856-0D9A5C8D-DA0B-47E1-A41B-1375F1FA0BF9Q27659044-4C1A55F3-33FA-4F2B-815D-A454560C7F50Q27702518-B455EF5F-F2B7-441E-BD34-B00D139A87AAQ28242369-70F6A02D-33F7-4B3B-AE16-8C995B3A9331Q28547855-8FA284E0-886F-4548-BD98-377824607053Q28555091-2340E73C-7860-4EC4-B444-2D29692D5B12Q28650538-83413000-D113-434E-AF06-B73E241FB708Q28660808-3BA4EC90-AA7C-46DD-9199-A19BCBC4B93CQ30430442-FB805DCB-EFF0-4B01-85CE-FA2F035D8E31Q30488815-266212A0-2E55-44AF-A68B-189A1EE04DB1Q33511765-51EC2C3B-FF68-4B65-A9DE-5E26F92A3B68Q33522199-06F2AE06-C60A-4CAE-83C7-9EF11B67B3E5Q33569694-AE22836B-5FDB-46F3-9D44-A5005ACEF7B7Q33808030-860D9DFA-547C-4390-AEB5-24C0581C636AQ33893113-C8A59E0D-4E40-4D38-9C9F-49F06F684BC8Q34001269-079A69A1-82AB-42BB-B727-F389782998AAQ34124142-0BAB76A7-1CD2-4A58-98A0-1196356D563FQ34154435-21268F6C-E992-4205-B15B-47B1F63364F9Q34282670-4C03B552-A1C9-4282-9476-4403017A94AAQ34390229-BCD8C3FF-8575-4A5D-BD7C-3066B3F3611EQ34626953-0D8E75EA-460D-455F-9A78-CE7168DE9D8DQ34752496-4C307430-32E3-4783-BFC3-423C81C4423BQ35419266-C051BEC0-C72D-4ED2-9CC3-36ECD7DAD7AFQ35702741-606D58D8-4DED-4366-ADF5-C0755DB06672Q36256789-77E310E8-F700-4552-97B3-52F14DB6585EQ36281061-C18B0E73-CA4F-4632-96AF-13B6950D1756Q37240475-BDDBD299-E843-450D-8194-0A721882F955Q37655104-AC7454D0-2F53-47E5-9B70-0EC9958F2EB5Q37987356-E1D138D0-6863-4FFF-B432-A1B0271F3343Q38079806-4445C59B-FDA9-46B9-842C-1F77E172B650Q38253280-949EAA29-9EC1-49CA-94BC-1E7F64D06656Q38430706-9393A13C-9FB6-4BA4-A2CF-73ECA2DF5A43Q38455086-F767E7E0-88EA-49DB-BDD6-5BB661DC7F7FQ38580461-39575238-8D46-42D0-8824-B1A853D66F39Q38874025-CE917D5B-29DA-4684-A2EC-BEE9118503CAQ39915228-7786EE95-3010-4E65-B416-BC68C7362CBEQ41449200-264DF391-D56C-417C-A044-BAFB4A8C05CFQ41831853-D325CC1E-8390-49D0-9D9F-28C6D3CE6211
P2860
Open access chemical and clinical probes to support drug discovery
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Open access chemical and clinical probes to support drug discovery
@ast
Open access chemical and clinical probes to support drug discovery
@en
Open access chemical and clinical probes to support drug discovery
@nl
type
label
Open access chemical and clinical probes to support drug discovery
@ast
Open access chemical and clinical probes to support drug discovery
@en
Open access chemical and clinical probes to support drug discovery
@nl
prefLabel
Open access chemical and clinical probes to support drug discovery
@ast
Open access chemical and clinical probes to support drug discovery
@en
Open access chemical and clinical probes to support drug discovery
@nl
P2093
P356
P1476
Open access chemical and clinical probes to support drug discovery
@en
P2093
Chas Bountra
David J Kerr
Timothy M Willson
P2888
P304
P356
10.1038/NCHEMBIO0709-436
P407
P50
P577
2009-07-01T00:00:00Z